Clopidogrel with or without omeprazole in coronary artery disease.
By Deepak L. Bhatt, B. Cryer, C. Contant, Marc Cohen, Á. Lanas, T. Schnitzer, T. Shook, P. Lapuerta, M. Goldsmith, L. Laine and 3 more. New England Journal of Medicine, 2010
1,181 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Pharmacology
View Paper: https://www.semanticscholar.org/paper/6268b06946327f30bb048efa62045cd1f7d533b0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- G. Fonarow
- J. Halperin
- Jose Luis Zamorano
- Hani Jneid
- Judith Hochman
- Allan S. Jaffe
- M. Creager
- Stephan Windecker
In Pharmacology
Citations in the corpus
- 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. (2013, background): “Proton-pump inhibitors, most prominently omeprazole, can interfere with clopidogrel metabolism and result in diminished in vitro antiplatelet effect,(291) but it does not appear that this pharmacokinetic effect translates into worse clinical outcomes.(291,292) Prasugrel, an alternative thienopyridin”
- 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, background): “Proton pump inhibitors should be prescribed in patients with NSTE-ACS with a history of gastrointestinal bleeding who require triple antithrombotic therapy with a vitamin K antagonist, aspirin, and a P2Y12 receptor inhibitor (27,242,243).”
- [2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS.] (2018, background): “A PPI in combination with DAPT is recommended [70, 79, 80, 86, 87].”